ReviewCurrent pharmaceutical design2015
Biomarkers predicting a need for intensive treatment in patients with early arthritis.
Review in Current pharmaceutical design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Galectin-1 levels do not predict outcomes in undifferentiated arthritis: a two-year prospective observational study.Frontiers in immunology · 2026Observational
- Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Article
- Article
- Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.Arthritis research & therapy · 2020Article
- Validation of galectin-1 as potential diagnostic biomarker of early rheumatoid arthritis.Scientific reports · 2020Article
- Identification of a HumanFrontiers in immunology · 2020Article
- An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.Frontiers in endocrinology · 2019Review
- Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives.RMD open · 2019Review
- Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.Scientific reports · 2018Article
- Rheumatoid Arthritis: A Brief Overview of the Treatment.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2018Review
- Managing Rheumatoid Arthritis with Dietary Interventions.Frontiers in nutrition · 2017Review
- Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study.BMC musculoskeletal disorders · 2016Article
- Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications.Therapeutic advances in musculoskeletal disease · 2016Review
- STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis.PloS one · 2016Article
- Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity.PloS one · 2016Article
- Advances in use of immunomodulatory agents--a rheumatology perspective.Nature reviews. Gastroenterology & hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The heterogeneous nature of rheumatoid arthritis (RA) complicates early recognition and treatment. In recent years, a growing body of evidence has demonstrated that intervention during the window of opportunity can improve the response to treatment and slow- or even stop-irreversible structural changes. Advances in therapy, such as biologic agents, and changing approaches to the disease, such as the treat to target and tight control strategies, have led to better outcomes resulting from personalized treatment to patients with different prognostic markers. The various biomarkers identified either facilitate early diagnosis or make it possible to adjust management to disease activity or poor outcomes. However, no single biomarker can bridge the gap between disease onset and prescription of the first DMARD, and traditional biomarkers do not identify all patients requiring early aggressive treatment. Furthermore, the outcomes of early arthritis cohorts are largely biased by the treatment prescribed to patients; therefore, new challenges arise in the search for prognostic biomarkers. Herein, we discuss the value of traditional and new biomarkers and suggest the need for intensive treatment as a new surrogate marker of poor prognosis that can guide therapeutic decisions in the early stages of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.